Skip to main content
SpringerLink
Log in

Aktuelle Studien zum Ovarialkarzinom

  • Topic_Ovarialkarzinom
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Sowohl für die Primärtherapie als auch die Rezidivsituation des Ovarialkarzinoms wurden in den vergangenen Jahrzehnten Chemotherapeutika mit guter Wirksamkeit zur Verbesserung der Prognose identifiziert. Zur Ergänzung der Chemotherapie werden seit mehreren Jahren weitere interessante Therapieansätze mit zielgerichteten Medikamenten untersucht. Nach der antiangiogenen Substanz Bevacizumab im Dezember 2011 erfolgte nun mit dem Poly-ADP-Ribose-Polymerase(PARP)-Inhibitor Olaparib bereits die zweite Zulassung einer solchen zielgerichteten Substanz für die Therapie des Ovarialkarzinoms. Im folgenden Artikel sollen aktuelle Konzepte positiver Studien mit unterschiedlichen Therapeutika zum Ovarialkarzinom vorgestellt und diskutiert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. du Bois A et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329

    Article  PubMed  Google Scholar 

  2. Mahner S et al (2013) Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer 49:142–149, doi:10.1016/j.ejca.2012.07.023

    Article  CAS  PubMed  Google Scholar 

  3. Ozols RF et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200, doi:10.1200/JCO.2003.02.153

    Article  CAS  PubMed  Google Scholar 

  4. Mahner S, Burges A (2014). Quality of life as a primary endpoint in ovarian cancer trials. Lancet Oncol 15:363–364, doi:10.1016/S1470-2045(14)70084-1

    Article  PubMed  Google Scholar 

  5. Pignata, S et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396–405, doi:10.1016/S1470-2045(14)70049-X

    Article  CAS  PubMed  Google Scholar 

  6. Perren TJ et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. New Engl J Med 365:2484–2496, doi:10.1056/NEJMoa1103799

    Article  CAS  PubMed  Google Scholar 

  7. Burger RA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl J Med 365:2473–2483, doi:10.1056/NEJMoa1104390

    Article  CAS  PubMed  Google Scholar 

  8. Aghajanian C et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045, doi:10.1200/JCO.2012.42.0505

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Pujade-Lauraine E et al (2012) AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30s: abstr LBA5002

  10. Monk BJ et al (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:799–808, doi:10.1016/S1470-2045(14)70244-X

    Article  CAS  PubMed  Google Scholar 

  11. du Bois, A et al (2014) Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32:3374–3382, doi:10.1200/JCO.2014.55.7348

    Article  PubMed  Google Scholar 

  12. du Bois, A et al (2013) AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 23: abstr LBA01

  13. Ledermann J et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med 366:1382–1392, doi:10.1056/NEJMoa1105535

    Article  CAS  PubMed  Google Scholar 

  14. Ledermann J et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–861, doi:10.1016/S1470-2045(14)70228-1

    Article  CAS  PubMed  Google Scholar 

  15. Oza AM et al (2014) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16(1):87–97, doi:10.1016/S1470-2045(14)71135-0

    Article  PubMed  Google Scholar 

  16. Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443, doi:10.1097/PAS.0b013e3181cf3d79

    Article  PubMed Central  PubMed  Google Scholar 

  17. Farley J et al (2013) Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14:134–140, doi:10.1016/S1470-2045(12)70572-7

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Mahner S, Pfisterer J (2013) Towards individualised treatment in ovarian cancer. Lancet Oncol 14:101–102, doi:10.1016/S1470-2045(13)70006-8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    Sven Mahner, Linn Wölber & Fabian Trillsch

  2. Klinik für Onkologie, Hämatologie und Knochenmarkstransplantation, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    Gunhild von Amsberg

  3. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

    Felix Hilpert

  4. Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen u. Marburg GmbH, Marburg, Deutschland

    Klaus Baumann

  5. Frauenklinik, Universitätsklinikum Tübingen, Tübingen, Deutschland

    Stefan Kommoss

  6. Frauenklinik, Universitätsklinikum Ulm, Ulm, Deutschland

    Nikolaus de Gregorio

  7. Kliniken Essen-Mitte, Klinik für Gynäkologische Onkologie, Essen, Deutschland

    Philipp Harter

Authors
  1. Sven Mahner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linn Wölber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gunhild von Amsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felix Hilpert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Klaus Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefan Kommoss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nikolaus de Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Philipp Harter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fabian Trillsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Mahner.

Additional information

Interessenkonflikt

S. Mahner, L. Wölber, G. von Amsberg, F. Hilpert, K. Baumann, S. Kommoss, N. de Gregorio, P. Harter und F. Trillsch geben an, dass die Autoren finanzielle Förderung wissenschaftlicher Projekte sowie klinischer Studien, Honorare für Vorträge oder Beratungstätigkeit durch folgende Firmen erhalten haben : AstraZeneca, GlaxoSmithKline, Janssen-Cilag, Lilly, MEDAC Oncology, PharmaMar, Roche, Tesaro.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahner, S., Wölber, L., von Amsberg, G. et al. Aktuelle Studien zum Ovarialkarzinom. best practice onkologie 10, 18–23 (2015). https://doi.org/10.1007/s11654-015-0158-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-015-0158-9

Search

Navigation